Medicine & Life Sciences

1. Adenocarcinoma 100%
2. Esophagogastric Junction 82%
3. pembrolizumab 44%
4. Esophageal Neoplasms 43%
5. ramucirumab 42%
6. Neoplasms 37%
7. Survival 31%
8. Chemoradiotherapy 28%
9. Stomach 27%
10. margetuximab 21%
11. Adjuvant Chemotherapy 20%
12. erbB-2 Genes 20%
13. Colonic Neoplasms 20%
14. Drug Therapy 19%
15. Therapeutics 18%
16. Gene Amplification 17%
17. Paclitaxel 15%
18. human ERBB2 protein 15%
19. Trastuzumab 14%
20. Carcinoma 14%
21. Microsatellite Instability 14%
22. Barrett Esophagus 11%
23. Colon 11%
24. Confidence Intervals 11%
25. Disease-Free Survival 11%
26. Monoclonal Antibodies 10%
27. ErbB Receptors 10%
28. Panitumumab 10%
29. Progression-Free Survival 10%
30. Combination Drug Therapy 10%
31. defactinib 9%
32. Photons 9%
33. Protons 9%
34. tipiracil 9%
35. Platinum 9%
36. Genetic Variation 9%
37. Body Mass Index 9%
38. Pancreatic Neoplasms 8%
39. Safety 8%
40. Obesity 8%
41. T-Lymphocytes 8%
42. Vascular Endothelial Growth Factor Receptor-2 8%
43. B7-H1 Antigen 8%
44. Induction Chemotherapy 7%
45. Cisplatin 7%
46. Single Nucleotide Polymorphism 7%
47. Immunotherapy 7%
48. Meta-Analysis 7%